The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
分析師的判決：5位專家眼中的艾伯維
5 analysts have expressed a variety of opinions on AbbVie (NYSE:ABBV) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在過去的一個季度中，有5位分析師對艾伯維（紐約證券交易所代碼：ABBV）表達了各種觀點，從看漲到看跌，提出了各種各樣的觀點。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表彙總了他們最近的評級，闡明瞭過去30天內情緒的變化，並將其與前幾個月進行了比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $190.4, a high estimate of $200.00, and a low estimate of $180.00. Highlighting a 0.18% decrease, the current average has fallen from the previous average price target of $190.75.
分析師12個月目標股價的見解得以公佈，平均目標股價爲190.4美元，最高估計爲200.00美元，低估值爲180.00美元。當前的平均價格已從之前的190.75美元的平均目標股價下跌，這凸顯了0.18％的跌幅。
Investigating Analyst Ratings: An Elaborate Study
調查分析師評級：一項詳盡的研究
The perception of AbbVie by financial experts is...
金融專家對艾伯維...
登入免費觀看全文
登入/註冊